Last reviewed 2026-04-19 · How we verify

Vindesin

At a glance

Approved indications

• Acute lymphoid leukemia
• Chronic myeloid leukemia
• Malignant melanoma
• Malignant tumor of lung

Common side effects

No common side effects on file.

Key clinical trials

• Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (Phase 3)
• Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma (Phase 3)
• MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) (Phase 2)
• A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-cell Lymphoma (Phase 2)
• A Phase I/II Study of Golidocitinib in Combination with CHOP in Patients with Newly Diagnosed Peripheral T Cell Lymphoma (Phase 1)
• Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With (Phase 3)
• Clinical Efficacy of MOAP Regimen for Relapsed/Refractory Classical Hodgkin's Lymphoma as a Rescue Therapy After Ineffective Treatment of Additional Low-dose Decitabine to Anti-PD-1 Antibody Camrelizu (Phase 1)
• Modified BFM (Berlin-Frankfurt-Munster)Backbone Therapy for Chinese Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma (Phase 3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.